Adapt Pharma gets FDA approval for 2-mg Narcan Nasal Spray

SILVER SPRING, Md. — The Food and Drug Administration has approved a 2-mg formulation of Adapt Pharma’s Narcan Nasal Spray, the company announced Wednesday. 

 

The 2-mg dose is approved for use in patients who are opioid dependent and expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. 

 

The FDA’s approval of the new formulation comes a little more than a year after it approved the nasal spray in a 4-mg formulation.